M Keller1, R Arora2, G Schmiedle1, T Kastenberger1. 1. Department für Unfallchirurgie, Medizinische Universität Innsbruck, Anichstraße 35, 6020, Innsbruck, Österreich. 2. Department für Unfallchirurgie, Medizinische Universität Innsbruck, Anichstraße 35, 6020, Innsbruck, Österreich. rohit.arora@tirol-kliniken.at.
Abstract
BACKGROUND: Dupuytren's disease as a benign fibroproliferative disease leads to hyperplasia of the collagen fibers of the fascia of the palm, which can result in severe impairment of the functionality of the hand. OBJECTIVES: Examination of the significance of non-operative treatment of Dupuytren's disease with injectable collagenase clostridium histolyticum (CCH) METHODS: Observation of 120 patients treated with injectable collagenase. Documentation of the range of motion before the intervention, 12 months after the intervention, and documentation of any adverse events. RESULTS: All in all, 120 patients were treated (107 male, 13 female) (mean age 62 years, range 30-84 years). In 49% the little finger, in 44% the ring finger, in 4% the middle finger, and in 3% the index finger were treated. Full release was accomplished in 71%, partial release in 26%, and no change in 3% of the patients. The median contracture before the treatment was 37° for the metacarpophalangeal (MP) joint (range 25-100°) and 51° for the proximal interphalangeal (PIP) joint (range 30-97°). After 12 months, the mean contracture for the MP joint was 9° (range 0-25°) and 21° (range 10-36°) or the PIP joint. Adverse events occurred in 96% of patients within 3 months after treatment. No tendon ruptures, anaphylactic reactions, nerve, or ligament injuries were observed.
BACKGROUND:Dupuytren's disease as a benign fibroproliferative disease leads to hyperplasia of the collagen fibers of the fascia of the palm, which can result in severe impairment of the functionality of the hand. OBJECTIVES: Examination of the significance of non-operative treatment of Dupuytren's disease with injectable collagenase clostridium histolyticum (CCH) METHODS: Observation of 120 patients treated with injectable collagenase. Documentation of the range of motion before the intervention, 12 months after the intervention, and documentation of any adverse events. RESULTS: All in all, 120 patients were treated (107 male, 13 female) (mean age 62 years, range 30-84 years). In 49% the little finger, in 44% the ring finger, in 4% the middle finger, and in 3% the index finger were treated. Full release was accomplished in 71%, partial release in 26%, and no change in 3% of the patients. The median contracture before the treatment was 37° for the metacarpophalangeal (MP) joint (range 25-100°) and 51° for the proximal interphalangeal (PIP) joint (range 30-97°). After 12 months, the mean contracture for the MP joint was 9° (range 0-25°) and 21° (range 10-36°) or the PIP joint. Adverse events occurred in 96% of patients within 3 months after treatment. No tendon ruptures, anaphylactic reactions, nerve, or ligament injuries were observed.
Entities:
Keywords:
Collagenase; Dupuytreny; Finger; Non surgical treatment; Palmar fibromatosis
Authors: Laurence A Levine; Beatrice Cuzin; Stephen Mark; Martin K Gelbard; Nigel A Jones; Genzhou Liu; Gregory J Kaufman; James P Tursi; David J Ralph Journal: J Sex Med Date: 2014-11-12 Impact factor: 3.802
Authors: David Gilpin; Stephen Coleman; Stephen Hall; Anthony Houston; Jeff Karrasch; Nigel Jones Journal: J Hand Surg Am Date: 2010-12 Impact factor: 2.230
Authors: Martin Gelbard; Irwin Goldstein; Wayne J G Hellstrom; Chris G McMahon; Ted Smith; James Tursi; Nigel Jones; Gregory J Kaufman; Culley C Carson Journal: J Urol Date: 2013-01-31 Impact factor: 7.450
Authors: Dayne T Mickelson; Shelley S Noland; Andrew J Watt; Kathleen M Kollitz; Nicholas B Vedder; Jerry I Huang Journal: J Hand Surg Am Date: 2014-09-04 Impact factor: 2.230